SEC Form 4 · accession 0001127602-17-009091
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Feb 27, 2017
Accepted (ET)
Mar 1, 2017 · 1:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F1 | $5.51 | Feb 27, 2017 | A | 175,000 | A | Feb 27, 2018 | Feb 27, 2027 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.